A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates

Update Il y a 4 ans
Reference: EUCTR2004-000511-25

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the effectiveness of AMG 162 in reducing urinary N-telopeptide (uNTx) below 50 nM BCE / mM creatinine in advanced cancer subjects with bone metastases (including multiple myeloma subjects with bone disease) with uNTx levels above 50 nM BCE / mM creatinine during intravenous bisphosphonate treatment.


Inclusion criteria

  • Bone metastases of solid tumors (except lung) or multiple myeloma bone disease

Links